Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Keryx Biopharmaceuticals, Inc. Announces Zerenex™ Phase 3 Data Presented at the 2013 World Congress of Nephrology


News provided by

Keryx Biopharmaceuticals, Inc.

03 Jun, 2013, 12:39 GMT

Share this article

Share toX

Share this article

Share toX

NEW YORK, June 3, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced the presentation of updated efficacy and safety data from the Phase 3 long-term clinical trial of Zerenex (ferric citrate), the Company's ferric iron-based phosphate binder drug candidate for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis. Dr. Julia Lewis, Professor of Medicine, Department of Nephrology, Vanderbilt University School of Medicine, and member of the Executive Committee of the Collaborative Study Group, and Study Chair of the Zerenex Phase 3 registration program, presented the updated dataset from the study entitled "A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis," in a symposium held earlier today in Hong Kong, during the 2013 World Congress of Nephrology (WCN) and a poster presented yesterday, Sunday, June 2, 2013.

Study Design

This Phase 3 long-term study was a multicenter, randomized, open-label, safety and efficacy clinical trial in 441 ESRD patients on hemodialysis or peritoneal dialysis. The study consisted of a 2-week washout period followed by a 52-week Safety Assessment Period (SAP) in which subjects were randomized 2:1 to receive either Zerenex or an active control (Renvela® [sevelamer carbonate] and/or Phoslo® [calcium acetate]). The 52-week SAP was followed by a 4-week Efficacy Assessment Period (EAP). During the EAP, only those subjects randomized to treatment with Zerenex during the SAP, and completed the 52-week SAP, were randomized in a 1:1 ratio to either continue treatment with Zerenex or switch to placebo for a 4-week treatment period. Subjects were titrated during the study to achieve normal serum phosphorus levels of 3.5 to 5.5 mg/dL. Zerenex was administered using a 1 gram oral caplet formulation.

Oral iron therapy was not permitted during the course of the study. Intravenous (IV) iron therapy was not permitted if a subject's serum ferritin level was greater than 1,000 ng/mL or transferrin saturation (TSAT) was greater than 30%. The use of erythropoiesis-stimulating agents (ESAs) was at the physician's discretion.

Study Efficacy Results

Dr. Lewis' presentation confirmed that Zerenex met the pre-defined primary and key secondary endpoints, highlighting that Zerenex is an efficacious and safe oral phosphate binder that controls serum phosphorus, increases iron stores as measured by serum ferritin and TSAT, and reduces the use of IV iron and ESAs, while sustaining hemoglobin as compared to the active control group.

The following results from the study were presented in the oral presentation given by Dr. Lewis on Monday, June 3, 2013 (Hong Kong time) at the WCN.

Table 1 - Primary Endpoint: Zerenex effectively controls serum phosphorus in the EAP.

Serum Phosphorus (mg/dL)

Zerenex
N=92

Placebo
N=91

Week 52 Baseline, Mean (SD)

5.1 (1.2)

5.4 (1.5)

Week 56(1), Mean (SD)

4.9 (1.3)

7.2 (1.8)

Change from Baseline

-0.2

+1.8

LS Mean (SE) Treatment Difference(2)

Treatment Difference P-Value(2)

-2.27 (0.21)

p<0.0001


(1) Last observation carried forward was used for missing data.
(2) The Least Squares (LS) Mean treatment difference and p-value is created via an ANCOVA model with treatment as the fixed effect and baseline as the covariate.

Table 2: Serum phosphorus was controlled over the 52-week SAP. Subjects were titrated to goal (3.5 to 5.5 mg/dL). There was no statistical or clinical difference between the two groups in managing serum phosphorus over 52 weeks.

Serum Phosphorus (mg/dL)

Mean (SD)(1)

Zerenex
N=281

Active Control
N=146

Day 0 (Study Baseline)

7.4 (1.6)

7.6 (1.7)

Week 12

5.4 (1.5)

5.3 (1.6)

Week 24

5.3 (1.6)

 5.5 (1.5)

Week 36

5.2 (1.5)

5.3 (1.6)

Week 52

5.4 (1.6)

5.4 (1.6)

(1) Last observation carried forward was used for missing data.

Table 3 - Secondary Endpoint: Zerenex increases serum ferritin as compared to Active Control.

Serum Ferritin (ng/mL)

Mean (SD)(1)

Zerenex
N=252

Active Control
N=135

Day 0 (Study Baseline)

593 (293)

609 (308)

Week 12

751 (384)

649 (326)

Week 24

846 (416)

652 (304)

Week 36

862 (443)

631 (328)

Week 52

Treatment Difference P-Value2

898 (489)

p<0.0001

624 (361)

 

(1) Last observation carried forward was used for missing data.
(2) P-value of treatment difference is created via an ANCOVA model with treatment as the fixed effect and baseline as the covariate.

Table 4 - Secondary Endpoint: Zerenex increases TSAT as compared to Active Control.

TSAT (%)

Mean (SD)(1)

Zerenex
N=252

Active Control
N=135

Day 0 (Study Baseline)

31 (11)

31 (12)

Week 12

40 (16)

31 (12)

Week 24

40 (15)

31 (12)

Week 36

40 (16)

30 (11)

Week 52

Treatment Difference P-Value(2)

39 (17)

p<0.0001

30 (11)

 

(1) Last observation carried forward was used for missing data.
(2) P-value of treatment difference is created via an ANCOVA model with treatment as the fixed effect and baseline as the covariate.

Dr. Lewis noted that TSAT and ferritin scores in the Zerenex arm achieved a statistical plateau, in regard to TSAT levels at Week 12 and to ferritin levels at Week 36, compared to Week 52 (end of the SAP).

Table 5 - Secondary Endpoint: Zerenex decreases IV Iron use as compared to Active Control.

Cumulative IV Iron Use

Zerenex
 N=272

Active Control
N=137

Median Daily Intake (mg/day)(1)

1.86

3.84

% Decrease

Treatment Difference P-Value(2)

-52%

p<0.0001


(1) IV iron intake is calculated as the total IV iron intake during the study divided by the total number of days on study drug during the study.
(2) P-value of treatment difference utilizes two-sided Wilcoxon Rank Sum Test.

Table 6: Zerenex reduces the need for IV Iron (p<0.0001) as compared to Active Control.

% of Subjects Off IV iron

Zerenex

Active Control

Last 9 Months of Study

42%

11%

Last 6 Months of Study

58%

24%

Table 7 - Secondary Endpoint: Zerenex decreases ESA use as compared to Active Control.

Cumulative ESA Use

Zerenex
 N=272

Active Control
N=141

Median Daily Intake (units/day)(1)

756

993

% Decrease

Treatment Difference P-Value(2)

-24%

p<0.05


(1) ESA intake is calculated as the total ESA intake during the study divided by the total number of days on study drug during the study.
(2) P-value of treatment difference utilizes two-sided Wilcoxon Rank Sum Test.

Table 8: Hemoglobin well-maintained with Zerenex in the SAP as compared to Active Control despite significantly lower IV iron and ESA use.

Hemoglobin (g/dL)

Mean (SD)(1)

Zerenex
N=245

Active Control
N=132

Day 0 (Study Baseline)

11.6 (1.2)

11.7 (1.2)

Week 12

11.8 (1.4)

11.5 (1.3)

Week 24

11.6 (1.4)

11.4 (1.2)

Week 36

11.5 (1.4)

11.3 (1.2)

Week 52

Treatment Difference P-Value(2)

11.4 (1.5)

P<0.05

11.1 (1.4)

 

(1) Last observation carried forward was used for missing data.
(2) P-value of treatment difference is created via an ANCOVA model with treatment as the fixed effect and baseline as the covariate.

Study Safety Results

Dr. Lewis indicated that Zerenex was safe and well-tolerated in the study and provided the below additional safety data.

Table 9: Zerenex arm incurred a lower rate of serious adverse events (SAEs) as compared to Active Control.

Deaths, SAEs and notable SAEs by
System Order Class(1)

Zerenex

Active Control

Subjects exposed to Study drug (n)

289

149

Deaths, n (%)

13 (4.5%)

8 (5.4%)

Subjects with an SAE, n (%)

114 (39.4%)

73 (49.0%)

Infections and Infestations, n (%)

36 (12.5%)

27 (18.1%)

Vascular Disorders, n (%)

22 (7.6%)

14 (9.4%)

Gastrointestinal Disorders, n (%)

20 (6.9%)

18 (12.1%)

Cardiac Disorders, n (%)

20 (6.9%)

17 (11.4%)

(1) Subjects may have more than one SAE.

Ron Bentsur, the Company's Chief Executive Officer, commented, "The data presented at WCN corroborates the top-line data presented earlier this year and further highlights Zerenex's highly-differentiated product profile. We believe that Zerenex, if approved, can potentially change practice patterns in dialysis and chronic kidney disease and improve patients' lives." Mr. Bentsur added, "We look forward to the presentations of additional data from the study at upcoming medical conferences."

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Keryx has completed a U.S.-based Phase 3 clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA, and the New Drug Application filing with the FDA and the Marketing Authorization Application filing with the EMA are pending submission. Zerenex is also in Phase 2 development in the U.S. for the management of phosphorus and iron deficiency in anemic patients with Stages 3 to 5 non-dialysis dependent chronic kidney disease. In addition, Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has filed its New Drug Application for marketing approval of ferric citrate in Japan for the treatment of hyperphosphatemia in patients with chronic kidney disease. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those relating to the results of clinical trials, and the clinical benefits to be derived from Zerenex (ferric citrate), as well as any business prospects for Zerenex, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: risks related to the timing for submission of the NDA and MAA and whether the FDA and EMA, respectively, will accept such submissions for review following submission and ultimately approve them; whether the FDA and EMA will concur with the our interpretation of our Phase 3 study results or the conduct of the study; whether, if Zerenex receives approval, it will be successfully distributed and marketed; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.